JD Health InternationalJDHIF 90 Return-on-Tangible-Equity is 9.84% as of Dec. 2025, which is 108% above its 10-year median of 4.73. GuruFocus rates JDHIF with a GF Score™ of 90/100 and a GF Value™ of $10.42. The stock has 1 warning sign investors should review. Among 581 Healthcare Providers & Services companies, JD Health International ranks worse than 50.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JD Health International's annualized net income for the quarter that ended in Dec. 2025 was $789 Mil. JD Health International's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $8,023 Mil. Therefore, JD Health International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 9.84%.
The historical rank and industry rank for JD Health International's Return-on-Tangible-Equity or its related term are showing as below:
JDHIF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -642.77 Med: 4.73 Max: 30.02
Current: 9.73
During the past 9 years, JD Health International's highest Return-on-Tangible-Equity was 30.02%. The lowest was -642.77%. And the median was 4.73%.
JDHIF's Return-on-Tangible-Equity is ranked worse than 50.77% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 9.93
vs JDHIF: 9.73
JD Health International (OTCPK:JDHIF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JD Health International Return-on-Tangible-Equity Related Terms
JD Health International Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JD Health International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JD Health International Return-on-Tangible-Equity Chart
JD Health International Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, JD Health International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JD Health International Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, JD Health International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JD Health International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.84% mean?
JD Health International (JDHIF) has a Return-on-Tangible-Equity of 9.84% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JD Health International and its competitors. This is 108% above median its historical median of 4.73. According to the industry distribution chart, JD Health International ranks #295 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 50.8%.
Is JD Health International's Return-on-Tangible-Equity too high?
JD Health International's current Return-on-Tangible-Equity of 9.84% is 108% above median its 10-year median of 4.73. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 9.93. JD Health International's value of 9.84% is 0.9% below this industry median. Based on the distribution chart, JD Health International ranks #295 out of 581 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, JD Health International has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does JD Health International's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, JD Health International ranks #295 out of 581 companies for Return-on-Tangible-Equity. This places JD Health International in the lower half of its industry. The industry median Return-on-Tangible-Equity is 9.93. JD Health International's value of 9.84% is 0.9% below this benchmark. While the company's 10-year median is 4.73 vs. the industry median of 9.93, JD Health International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 9.93, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JD Health International's current Return-on-Tangible-Equity of 9.84% is 0.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JD Health International and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JD Health International's current Return-on-Tangible-Equity is 9.84%, which is 108% above median its own 10-year median of 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JD Health International stock overvalued right now?
JD Health International (JDHIF) has a current Return-on-Tangible-Equity of 9.84%. The stock's GF Value™ is $10.42, compared to a current price of $5.85 — trading 43.9% below its estimated fair value. The current Return-on-Tangible-Equity is 9.84%, which is 108% above median its 10-year median of 4.73 and 0.9% below the Healthcare Providers & Services industry median of 9.93. JD Health International's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JD Health International (JDHIF), the current Return-on-Tangible-Equity is 9.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JD Health International (JDHIF) Overvalued in 2026?
Based on GuruFocus' analysis, JD Health International stock appears to be undervalued.
The current stock price of $5.85 is trading 43.9% below its estimated GF Value™ of $10.42.
Key valuation signals for JDHIF:
Return-on-Tangible-Equity: 9.84% (108% above median its 10-year median of 4.73)
GF Value™: $10.42 vs. price of $5.85 (43.9% below fair value)
Industry Position: 0.9% below the Healthcare Providers & Services median (#295 of 581)
No single metric tells the full story. See the JDHIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
90GF Score
Get the complete analysis for JDHIF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JDHIF has been successfully added to your 
